In conclusion, serum JKAP correlates with disease severity, Th2 and Th17 secreted cytokines, ICAM‐1, and recurrence in AIS patients, indicating its potency to realize the risk stratification and consequently help clinicians provide individual treatment to each AIS patient. This evidence concerns the gene DUSP22 and androgen insensitivity syndrome.